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Summary.-Monoclonal antibody against an osteogenic-sarcoma cell line (791T) was
prepared by production and cloning of a somatic-cell hybrid between the mouse
myeloma P3-NS1 and spleen cells from 791T-immunized mice. Three clones of a
hybridoma producing antibody against 791T, as detected by 1251-labelled Protein A
binding, were tested against a range of normal and tumour cell targets to determine
the pattern of expression of the antigen detected. The 3 clones had identical activity.
They reacted strongly against 791T cells and another osteogenic sarcoma, 788T, and
more weakly against a further 2 from a total panel of 10 osteogenic-sarcoma lines.
The antibody was negative for fibroblasts from the donor of 791T, and for other
fibroblasts, human red blood cells, human peripheral mononuclear cells and sheep
red blood cells. When tested against a panel of unrelated tumours, they reacted
against individual cell lines derived from carcinomas of colon, lung, bladder and
cervix. These cross-reactions were not observed with other colon or lung carcinomas,
and it is suggested that the antibody was reacting with a tumour-associated antigen
expressed randomly on different tumour types, rather than specifically on osteogenic
sarcomas.
THE DETECTION of human tumour-
associated cell-surface antigens has mainly
been approached by in vitro methods,
though a number of studies have claimed
to demonstrate these antigens in vivo by
the elicitation of cutaneous delayed type
hypersensitivity reactions with tumour
extracts (Hollinshead et al., 1974). In vitro
methods involving cellular immunity have
often proved unreliable indicators of
antigenicity (reviewed by Baldwin &
Embleton, 1977), partly owing to the
presence of naturally reactive cells in
normal populations. This has led to the
exploitation of serological methods using
patients' sera or absorbed xenogeneic sera,
but again neither of these reagents is
completely satisfactory. The production
of monoclonal antibodies by somatic-cell
hybrids promises to revolutionize the
serology of human tumours by providing
reagents of superior precision and speci-
ficity. This approach has been claimed to
yield antibodies specific for cell-surface
antigens of malignant melanoma (Yeh
et al., 1979; Koprowski et al., 1978;
Carrel et al., 1980); colon carcinoma
(Koprowski etal., 1979) andneuroblastoma
(Kennet & Gilbert, 1979). We now report
the production of monoclonal antibodies
to an osteogenic-sarcoma cell line and
characterization ofits reactivity towards a
variety of other tumour types.
MATERIALS AND METHODS
Cells.-P3-NS1-Ag-4 (P3NS1) cells were
obtained from the Department of Genetics,
University of Oxford, by permission of
Professor W. F. Bodmer, having originated
from Dr C. Milstein, Department ofMolecular
Biology, University of Cambridge. The
P3NS1 cells were grown in suspension in
RPMI 1640 medium supplemented with 10%ANTI-SARCOMA MONOCLONAL ANTIBOD)Y
foetal calf serum (FCS) and 15 ,ug/ml 8-
azaguanine (Sigma, London).
Various lines of human tumour cells or
control fibroblasts were grown as monolayer
cultures in Eagle's minimum essential
medium (MEM) supplemented with 10%
foetal calf serum. These cells were used as
target cells, together with erythrocytes and
mononuclear cells freshly prepared from
heparinized blood of volunteer donors.
Immunization.-Male BALB/c mice w%ere
injected i.p. with 107 cells of an osteogenic
sarcoma cell line, 791T. One week later a
second i.p. inoculation of 107 791T cells was
given. The mice were then given a booster
inoculation of 2 x 106 791T cells by intra-
cardiac injection 5 days before their spleens
wrere removed for fusion.
Cellfusion.-Spleens were removed aseptic-
ally and cell suspensions were prepared by
teasing fragments in RPM1 1640 medium.
108 spleen cells were then fused with 107
P3NS1 cells, using 50% polyethylene glycol
as previously described (Gunn et al., 1980)
following the basic method of Galfre et al.,
(1977).
Supernatants were screened for reactivity
against 791T cells and other targets using a
125J-labelled Protein A binding test. Positive
hybridomas were cloned in 0-3Qo agar (Gunn
et al., 1980).
125I Protein A binding test.-The assay was
based on an 1251 anti-globulin binding test
described previously (Gunn et al., 1980;
Al-Sheikly et al., 1980). Trypsin-harvested
target cells were aliquoted at 105 per well in
round-bottomed Sterilin M24A microtest
plates, and sedimented by centrifugation.
They were incubated for 1 h on ice (in tripli-
cate) with 100ul of monoclonal hybridoma
supernatant, or in controls, with normal
washing medium (Hanks' balanced salt solu-
tion containing 0-1% bovine serum albumin)
or spent supernatant from P3NS1 cultures.
The cells were washed x 3 and incubated for
a further 1 h on ice with Protein A (Pharm-
acia) labelled with 1251 by the method of
Williams et al. (1977). The amount of protein
used was 5 ng per well, giving between 2 x 104
and 105 ct/min/well, according to the batch
used. The cells were washed x 6 and dried
down. After spraying wiith a plastic film
(Nobecutane) the wells were separated with
a band saw and the bound 1251 measured in
a gamma counter.
Absorption.-Hybridoma supernatant was
diluted 1:10 and absorbed in some tests with
cultured tumour cells at a concentration of
108 cells per ml of supernatant for 2 h at
ambient temperature. The cells were removed
by centrifugation and the absorbed super-
natant tested for reactivity against selected
targets (see text).
RESULTS
One fusion produced 48 growing hybrid
cultures from 48 explants. All were
screened for reactivity against 791T target
cells and 5 were found initially to react
significantly above control levels. Upon
repeated testing only two (designated
791T/36 and 791T/48) were consistently
positive, and these were further tested for
reactivity against several other target cell
lines (Figure). Both were positive for 791T
and a second osteogenic sarcoma cell line,
788T, and the 791T/36 supernatant was
also positive for a third osteogenic sar-
coma, 805T. Reactivity of 791T/36 against
a fourth sarcoma, 888T, was raised but not
significantly different from background.
All other tests were negative, and this
includes 3 fibroblastic lines derived from
the donor of the 791T cell line (860, 870
and 791SK, respectively). At this point the
791T/36 hybridoma was cloned in soft
agar.
Twelve clones were isolated and their
supernatants tested against 791T cells,
791SK skin fibroblasts and two other cell
lines (618 Lu normal lung cells and RAJ].
lymphoma cells). Nine clones were highly
reactive with 791T cells and 3 more weakly
so, but all were negative with the other
target cells (Table I). Three ofthe strongly
reactive clones were screened against an
extensive panel oftarget cells, as shown in
Table II. All 3 clones had similar activity,
presumably indicating that the 791/36
hybridoma culture might contain only one
positive clone. They gave positive anti-
body reactions against 4/10 osteogenic
sarcomas from individual patients, but
were completely negative with fibroblastic
cells, whether derived from the donor of
791T or from other patients. Two of the
allogeneic fibroblast controls (788SK and
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FIGuRE.-Specificity of anti-791T hybridoma supernatants. The supernatants from hybridoma
cultures 791T/36 and 791T/48 were tested against various target cells to test their specificity before
cloning. The background (ct/min with P3NSL medium) was 295 +35, and is converted to zero in the
figure, i.e. the histograms are corrected for background by subtraction. The vertical bars on the
histograms represent s.e.
TABLE I.-Reactivity of clones of Hybridoma 791T/36 against 791T osteogenic sarcoma
and control cell lines
1251 (ct/min_s.d.) bound to target cells
Osteogenic
Test sarcoma
supernatant 791T*
HBSS+BSAt 278+4
P3NS1 spent medium 279 + 50
791T/36 Clone 1 12082+402
Clone 2 14932+598
Clone 3 16905+ 261
Clone 4 16311+ 322
Clone 5 10700+ 388
Clone 6 13981+371
Clone 7 921+ 77
Clone 8 1174+44
Clone 9 1858+ 173
Clone 10 18383+ 1236
Clone 11 18018+ 63
Clone 12 11189+497
Skin
fibroblasts
791SK*
689 +15
410+ 55
326 + 30
380+ 21
404+ 34
316 + 40
339 + 29
361+11
292+ 14
501+ 51
316+ 16
334 + 24
657 +57
425 + 25
Lung
fibroblasts
618 Lu
396 + 36
366 + 6
575 + 52
549 + 22
447 + 6
433 + 33
318 + 8
471+ 9
307 + 63
369+44
455+43
488+ 19
608 + 118
435+57
Burkitt
lymphoma
Raji
694+ 31
485 + 96
719+ 29
522+ 114
444+ 71
473 + 164
591+ 41
632+ 132
259 + 36
329 + 36
226 +24
229 + 20
276 +25
323 + 97
* 791T and 7915K were derived from the same patient.
t Hanks' blanced salt solution +01% bovine serum albumin (washing medium).
805SK) were from donors ofsarcomas that
reacted positively (788T and 805T, respec-
tively). Erythrocytes from 9 control
donors (comprising all majorbloodgroups)
and their peripheral mononuclear cells
were all negative, as were sheep erythro-
cytes, a canine osteogenic sarcoma (73-
2295) and rat tumour cell lines. Tests
against 19 other human tumour cultures of
various types, however, revealed cross-
reactions against HeLa cells, EB33 pros-
tate carcinoma, HT29 colon carcinoma
I
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and A549 lung carcinoma cells. These
cross-reactions, and all the negative reac-
tions, were always reproducible upon
repeated testing.
Absorption tests
Supernatant from 791T/36 Clone 3 was
diluted and absorbed for 2 h with various
cell lines at a concentration of 108 cells/ml.
TABLE II.-Reactivity ofcertain 791T/36 clones against various target cells
Binding ratiot of 791T/36 clone
Cell line
791Tt
788T§
845T
805T
803T
836T
706T
781T
888T
792T
791SKt
788SK§
805SK
181SK
836SK
8601
870$
618Lu
74BM
HT29
HTC8
HRT18
734 B
SK Br 3
HS 578T
MeWo
Mel 57
Mel 2a
NK1-4
RPM1 5966
A549
A427
9812
HeLa
EB33
T24
PA-1
RAJI
73-2295
D23
KXD2
Sp4
Cell type
Osteogenic sarcoma
Skin fibroblasts
Tumour-derived
fibroblasts
Lung fibroblasts
Foetal marrow
Human erythrocytes
Human mononuclear
cells
Colon carcinoma
Breast carcinoma
Melanoma
Lung carcinoma
Cervix carcinoma
Prostate carcinoma
Bladder carcinoma
Ovarian carcinoma
Burkitt lymphoma
Sheep erythrocytes
Canine osteosarcoma
Rat hepatoma
Rat breast carcinoma
3
22-84***
46-82***
3-19*
2-63
1-45
0-78
1-89
1-83
1-08
1-12
0-99
0-90
1-41
2-14
1-31
1-39
1-09
1-68
1-50
0-61-0-91
0-61-1-24
6-66**
1-61
1-21
2-18
1-54
1-22
0-98
1-19
1-36
1-25
1-36
4-54**
1-09
1-39
55-52***
28-3***
1-50
1-61
1-26
1-00
1-10
0-78
1-01
1-25
4
25.60***
53-13***
5-58**
3-41*
1-45
0-73
2-49
2-06
1-13
1-23
0-77
NT
2-05
2-18
1-29
NT
1-04
1-63
1-69
0-61-1-35
0-70-2-00
7-10**
2-52
1-02
1-87
1-38
1-76
0-72
1-25
2-17
0-47
1-48
5-93**
1-31
1-22
53.95***
26.11***
1-76
1-50
1-06
0-56
1-43
0-98
1-12
1-15
10
22-84***
52-74***
NT¶
2-99*
NT
0-82
NT
1-92
1-12
NT
0-84
0-99
1-46
2-10
NT
1-48
0-95
1-83
NT
NT
0-63-1-28
6-85**
1-89
1-10
1-81
1-47
1-32
0-88
1-22
2-07
0-56
1-66
4-76**
1-10
0-94
53-58**
26.22***
1-48
1-43
0-60
0-57
1-34
0-88
1-10
1-27
t Binding ratio=mean ct/min with 791T/36 clone supernatant, divided by mean ct/min with P3NSL
spent medium. P3NS1 spent medium gave the same ct/min as washing medium. Statistical analysis of the
difference between ct/min for 791T/36 clone and ct/min for P3NS1 medium by the t test is indicated by:
***(P < 0-001); **(P < 0-01) and *(P < 0-05).
1 791T, 791SK, 860 and 870 were from the same patient (M.U.).
§ 788T and 788SK were from the same patient (P.R.).
805T and 805SK were from the same patient (Q.L.).
NT =Not tested.
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TABLE III.-Absorption of antibody from
791T/36 Clone 3 supernatant
Mean ct/min- Reduction
Background: on
Target Absorbing absorption
cells cellst unabsorbed absorbed§ (0)
791T 791T 377111 107 97-2
791T 788T 3771 296 92-1
791T EB33 3771 182 95-2
791T Mel2a* 2062211 15652 24-1
791T Mel57* 20622 17499 15-1
791T PA-I* 20622 18339 11-1
791T A549 20622 -798 100
788T 788T 4271 366 91-4
788T 791T 4271 296 93-1
A549 A549 6053 1481 75-5
A549 791T 6053 235 96-1
HT29 HT29 1697 512 69-8
HT29 791T 1697 412 75-7
EB33 EB33 5846 322 94-5
EB33 791T 5846 323 94-5
HeLa HeLa 2330 180 92-3
HeLa 791T 2330 240 89-7
t Cells marked * did not cross-react with the anti-
body in direct tests; all other cells in this Table did
so (see Table II).
t Ct/min with P3NS1 spent medium.
§ Supernatant 791T/36 Clone 3 was diluted 1:10
and absorbed with 108 cells/ml at room temperature
for 2 h.
jj The two indicated values were obtained in
separate experiments with different batches (and
1251 input levels) of labelled Protein A.
These conditions were based upon those
used successfully with a monoclonal anti-
body to a rat breast carcinoma, which has
a titre against relevant target cells of
1/1000 (Gunn et al., 1980); this was also
the titre empirically determined for 791T/
36 Clone 3. Table III shows data from
experiments in which the monoclonal
antibody was (a) absorbed by 791T cells
and tested against other cross-reactive
target cells, (b) absorbed with other
tumour cells and tested against 791T, or
(c) absorbed with, and tested against cells
other than 791T. Where the cross-tested
absorbing cells or target cells were reactive
with the antibody (Table II) reductions
ofbound ct/min ofbetween 70% and 90%
were obtained after absorption. When the
antibody was absorbed with non-cross-
reactive cells (Mel 2a, Mel 57, PA-1)
however, the reduction of activity against
791T cells was only 11-24%. These results
support the specificity of the antibody
demonstrable in direct tests.
DISCUSSION
Monoclonal antibodies were obtained
from the cloned hybridoma 791T/36,
which reacted preferentially with tumour
cells. The antibody was strongly reactive
with the immunizing osteogenic-sarcoma
cell line, 791T, but was negative with
fibroblasts obtained from the same patient
(791SK, 860 and 870). It was also strongly
reactive with a second osteogenic sarcoma,
788T, and more weakly reactive with
another, 805T, but was negative with skin
fibroblasts from the same patients (788SK
and 805SK, respectively). This clearly
demonstrates that the antibody was not
reacting against human species-associated
or histocompatibility antigens on the
sarcoma cells. The antibody also failed to
react with 25 other cultured human target
cell lines, so was not directed against FCS
components which are sometimes incor-
porated into the membrane of cells grown
in medium containing this as a supplement
(Embleton & Jype, 1978; Irie et al., 1974).
Red blood cells from volunteer donors,
including all the major blood groups, did
not react with the antibody, so it can not
have been directed against blood-group
antigens, which are sometimes expressed
on tumour cells. Other ahtigens which can
be discounted are DR antigens and Forss-
man antigen, since no reaction was
obtained with peripheral mononuclear
cells (containing both lymphocytes and
monocytes) from 9 different donors, or
with sheep red blood cells, respectively.
It thus seems certain that the antibody
was directed against a tumour-associated
antigen.
However, the antigen detected was not
shared by all the osteogenic sarcomas,
since only 4/10 were positive, and was not
exclusive to osteogenic sarcomas. Positive
(and reproducible) cross-reactions were
obtained with one cell line each derived
from carcinomas of colon, lung, prostate
and cervix. This does not represent a
tissue-related cross-reactivity, because 2
other colon carcinomas and 2 lung car-
cinoma celllines were negative. Rather,the
picture is one of a randomly expressed
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tumour-associated antigen not associated
with any particular histological type of
tumour.
This is at variance with the dogmatic
view that human tumours express antigens
common to tumours of a given tissue (dis-
cussed by Baldwin & Embleton, 1977),
which view appears to be supported by
some of the early studies on monoclonal
antibodies to human tumours, in which
tissue-related specificity was reported
(Koprowski et at., 1978; Steplewski et al.,
1979; Yeh et al., 1979; Koprowski et al.,
1979; Carrel et al., 1980). However, pre-
liminary results with clones derived from
the second anti-791T hybridoma, 791T/48,
confirm the present findings of random
antigen expression (Embleton et al., to be
published), andfurther supportisprovided
by cross-reactions we have observed with
anti-melanoma monoclonal antibodies (un-
published). Monoclonal antibodies poten-
tially offer the best means ofanalysing the
antigenic profiles of human solid tumours,
and we suggest that the emergent picture
may well be one ofa spectrum ofantigens,
one or several of which may be expressed
by any given tumour irrespective ofhisto-
logical type, perhaps in addition to dif-
ferentiation antigens which might be
tissue-related. If this eventually proves to
be a general rule, attempts to use mono-
clonalantibodies formonitoring ortherapy
of human tumours may have to depend
upon the use of panels of monoclonal
antibodies capable of recognizing many
different antigens.
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